Lupin outshines Ranbaxy on strong US sales

Lupin has built a US portfolio that is delivering consistently, while Ranbaxy's dependence on exclusivity sales is hampering it

The stock movement for pharma majors Ranbaxy Laboratories and Lupin captured the contrasting performance in the March quarter. While Lupin, which has been hitting highs recently managed to scale the all-time high mark on Wednesday, Ranbaxy closed almost three per cent down at Rs 443. Lupin continues to beat analyst expectations on a consistent basis, on the back of a strong product portfolio it has also scored on the domestic growth parameter, outshining larger peers. On the other hand, Ranbaxy’s US business growth is largely dependent on exclusivity launches, so revenues tend to ...